Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial

• Published in: International journal of gynecological cancer Vol. 16; no. 1; pp. 52 - 56
• Main Authors: Utsunomiya, H, Akahira, J, Tanno, S, Moriya, T, Toyoshima, M, Niikura, H, Ito, K, Morimura, Y, Watanabe, Y, Yaegashi, N
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.01.2006
• Subjects: Adenocarcinoma, Clear Cell - drug therapy; Adenocarcinoma, Clear Cell - mortality; Adenocarcinoma, Clear Cell - pathology; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer; Chemotherapy; Cisplatin - administration & dosage; Cisplatin - therapeutic use; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; Japan; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - mortality; Neoplasm Recurrence, Local - pathology; Neoplasm Staging; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - mortality; Ovarian Neoplasms - pathology; Ovaries; Paclitaxel - therapeutic use; Probability; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome; Japan
• ISSN: 1048-891X; 1525-1438
• DOI: 10.1136/ijgc-00009577-200601000-00009

The therapeutic effect of a combination of paclitaxel (PTX) and platinum (PLT) in ovarian clear cell adenocarcinoma (CC) patients with measurable disease has yet to be elucidated. In this study, we used retrospective review to evaluate the results of treatment with a combination of PTX and PLT in CC patients with measurable disease. A total of 28 patients with measurable residual CC (15 cases with primary disease, 13 cases with recurrent disease) treated with combination PTX-PLT chemotherapy was identified through medical records from ten institutions. Clinical response to chemotherapy was evaluated using Response Evaluation Criteria in Solid Tumors criteria. Of the 28 cases, 8 of 15 patients with primary disease (53.3%) and 3 of 13 patients with recurrent disease (23.1%) responded to PTX-PLT chemotherapy. The response rate for cases with late recurrent disease (>12 months) was 20% (1/5), whereas the rate was 25% (2/8) for cases with early recurrent (<12 months) or refractory disease. Our results indicate that the combination of PTX and PLT may have greater efficacy against CC than conventional PLT-based chemotherapy that does not include PTX.